Lemke A, Kayser O
Department of Pharmaceutical Technology, Biotechnology, Free University of Berlin, Germany.
Pharmazie. 2006 May;61(5):406-8.
Miltefosine has recently been introduced as leishmanicidal drug for oral administration (Impavido). Previous communications report about the use of liquid chromatography coupled with mass spectrometry detection to detect miltefosine in pharmaceutical preparations and biological fluids. We report about a new method to detect miltefosine using an evaporative light scattering detector (ELSD). The absolute recovery of the analyte was greater than 98.0%. The limit of quantification for miltefosine in plasma at a signal-to-noise ratio of 7.3 was 0.34 microg/ml. The precision of the assay yielded coefficients of variation ranging from 1.8 to 4.5% and an accuracy of 97-107%. Our method advances the qualitative and quantitative detection of miltefosine by combining rapid and efficient solid phase extraction and analysis with an evaporative light-scattering detector.
米替福新最近作为一种口服杀利什曼原虫药物(Impavido)被引入。此前的通讯报道了使用液相色谱-质谱检测法来检测药物制剂和生物流体中的米替福新。我们报告了一种使用蒸发光散射检测器(ELSD)检测米替福新的新方法。分析物的绝对回收率大于98.0%。在信噪比为7.3时,血浆中米替福新的定量限为0.34微克/毫升。该测定方法的精密度变异系数在1.8%至4.5%之间,准确度为97%至107%。我们的方法通过将快速高效的固相萃取与蒸发光散射检测器分析相结合,推进了米替福新的定性和定量检测。